June 11, 2018

Plant-Made E2 Glycoprotein Single-Dose Vaccine Protects Pigs against Classical Swine Fever

Introduction Classical Swine Fever (CSF) is a highly contagious hemorrhagic disease affecting pigs. CSF outbreaks have caused substantial economic damages to the swine industry worldwide, including a major outbreak in the Netherlands between 1997 and ...

Continue Reading

January 31, 2018

Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies

Introduction Therapeutic glycoproteins represent a predominant disease treatment category among biopharmaceuticals approved or in clinical development. N-linked glycosylation is a very important post-translational modification that can profoundly affect ...

Continue Reading

July 25, 2017

AzarGen Biotechnologies Granted European Patent for Plant-Made Production of Recombinant Human Surfactant Protein-B

AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), announced that it has received grant status for the patent application: PRODUCTION OF HUMAN PULMONARY SURFACTANT PROTEIN-B IN PLANTS (EP3013963) from the European Patent Office.

Continue Reading

July 12, 2017

U.S. Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology

AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa) announced that it has received grant status for the patent application: SYNTHETIC PROMOTER CONSTRUCT FOR TRANSGENE EXPRESSION (US9670497) from the US Patent office.

Continue Reading

April 25, 2017

AzarGen's Case for a Commercial Plant-Made Pharmaceutical Facility in South Africa

AzarGen Biotechnologies, South Africa’s only private plant-based biopharmaceutical company, is imagining a world-class commercial plant-made pharmaceutical facility for South Africa.

Continue Reading
1 2 3 4